Eleven NHS genomics medicine centres chosen for 100,000 genomes project

16 January 2015

NHS England has chosen the first eleven Genomic Medicine Centres across the country to lead the way in delivering the 100,000 Genomes Project.

The project will collect and decode 100,000 human genomes for medical research. The results could improve the prediction and prevention of disease, enable new and more precise diagnostic tests, and allow personalisation of drugs and other treatments to specific genetic variants.

Over the lifetime of the project NHS England’s ambition is to secure over 100 participating NHS trusts. A further wave of GMCs will be procured to ensure that there is comprehensive coverage across the NHS in England. Recruitment to the project will begin from 2 February 2015.

After samples are collected, they will be sent securely to genomics company Illumina who have been procured by Genomics England to sequence the whole genome and to analyse it. Results will be sent back to the NHS for validation and clinical action.

Professor Sir Bruce Keogh, NHS England’s National Medical Director, said: “This is an achievable ambition which positions Britain to unlock longstanding mysteries of disease on behalf of humankind. Embracing genomics will position us at the forefront of science and make the NHS the most scientifically advanced healthcare system in the world. This is the start of a unique, exciting journey that will bring benefits for patients, for the NHS and for society at large.”

Professor Sue Hill, the Chief Scientific Officer for England, who chaired the team evaluating the various applicant GMCs said: “The NHS has risen to both the challenge and opportunity of delivering its contribution to the 100,000 whole genomes project in the most extraordinary and unparalleled way. Locally in the NHS, there has been clearly demonstrated engagement and involvement of senior managers, clinical teams, clinical genetic and molecular pathology laboratories and critically patients and the public, all committed to using the science of whole genome sequencing to making a real and lasting difference for patient benefit.”

Life Sciences Minister George Freeman added: “Our understanding of genomics is transforming the landscape for disease diagnosis and medicines research. We want to make the UK the best place in the world to design and discover 21st century medicines which is why we have invested in the 100,000 Genomes Project. We also want to ensure NHS patients benefit which is why we have now selected NHS hospitals to help us sequence genomes on an unprecedented scale and bring better treatments to people with cancers and rare diseases for generations to come.”

Professor Mark Caulfield, Chief Scientist at Genomics England, said: “The creation of the new NHS Genomic Medicine Centres will play a key role in bringing together researchers, NHS clinicians and trainees to work on whole genome data that has never been collected on this scale before. We have a clear goal of accelerating the findings from the programme back into mainstream healthcare at the fastest possible pace, meaning more rapid results for patients.”

The chosen GMCs

The first wave of 11 designated Genomic Medicine Centres are:

  • East of England NHS GMC — designated for both cancer and rare disease. Led by Cambridge University Hospitals NHS Foundation Trust.
  • South London NHS GMC — designated for both cancer and rare disease. Led by Guy’s and St Thomas’ NHS Foundation Trust.
  • North West Coast NHS GMC — designated for both cancer and rare disease. Led by Liverpool Women’s NHS Foundation Trust.
  • Greater Manchester NHS GMC — designated for both cancer and rare disease. Led by Central Manchester University Hospitals NHS Foundation Trust.
  • University College London Partners NHS GMC — designated for both cancer and rare disease. Led by Great Ormond Street Hospital NHS Foundation Trust.
  • North East and North Cumbria NHS GMC — designated GMC for rare disease only. Led by The Newcastle upon Tyne Hospitals NHS Foundation Trust.
  • Oxford NHS GMC — designated for both cancer and rare disease. Led by Oxford University Hospitals Foundation Trust.
  • South West Peninsula NHS GMC — designated for both cancer and rare disease. Led by Royal Devon & Exeter NHS Foundation Trust.
  • Wessex NHS GMC — designated for both cancer and rare disease. Led by University Hospital Southampton NHS Foundation Trust.
  • Imperial College Health Partners NHS GMC — designated for both cancer and rare disease. Led by Imperial College Healthcare NHS Trust.
  • West Midlands NHS GMC — designated for both cancer and rare disease. Led by University Hospitals Birmingham NHS Foundation Trust.

To top